The Volume and Cost of Quality Metric Reporting.

Importance: US hospitals report data on many health care quality metrics to government and independent health care rating organizations, but the annual cost to acute care hospitals of measuring and reporting quality metric data, independent of resources spent on quality interventions, is not well known. Objective: To evaluate externally reported inpatient quality metrics for adult patients and estimate the cost of data collection and reporting, independent of quality-improvement efforts. Design, Setting, and Participants: Retrospective time-driven activity-based costing study at the Johns Hopkins Hospital (Baltimore, Maryland) with hospital personnel involved in quality metric reporting processes interviewed between January 1, 2019, and June 30, 2019, about quality reporting activities in the 2018 calendar year. Main Outcomes and Measures: Outcomes included the number of metrics, annual person-hours per metric type, and annual personnel cost per metric type. Results: A total of 162 unique metrics were identified, of which 96 (59.3%) were claims-based, 107 (66.0%) were outcome metrics, and 101 (62.3%) were related to patient safety. Preparing and reporting data for these metrics required an estimated 108 478 person-hours, with an estimated personnel cost of $5 038 218.28 (2022 USD) plus an additional $602 730.66 in vendor fees. Claims-based (96 metrics; $37 553.58 per metric per year) and chart-abstracted (26 metrics; $33 871.30 per metric per year) metrics used the most resources per metric, while electronic metrics consumed far less (4 metrics; $1901.58 per metric per year). Conclusions and Relevance: Significant resources are expended exclusively for quality reporting, and some methods of quality assessment are far more expensive than others. Claims-based metrics were unexpectedly found to be the most resource intensive of all metric types. Policy makers should consider reducing the number of metrics and shifting to electronic metrics, when possible, to optimize resources spent in the overall pursuit of higher quality.

Mapeamento dos bancos de dados em dispositivos médicos: revisão narrativa e o cenário brasileiro para avaliação com dados de mundo real (RWD) / Mapping of database in medical devices: review and the Brazilian scenario for evaluation with real world data (RWD)

Objetivo: Pretendeu-se mapear os bancos de dados governamentais em dispositivos médicos, na perspectiva pública com o intuito de contribuir como fonte para gerar dados de mundo real (RWD) e potencial para subsidiar estudos de Avaliação de Tecnologias em Saúde (ATS). Métodos: Realizada revisão narrativa na base de dados do Embase. Os critérios para inclusão de elegibilidade foram: i) dimensão ampla de RDW nos processos de gestão de tecnologias; e ii) aplicação de RDW em processos regulatórios, cobertura e ATS. Também foram consultados os sistemas do Ministério da Saúde e da Anvisa. Resultados: A busca retornou 1.185 resultados; após leitura dos resumos, foram selecionados 29 artigos, sendo 5 incluídos. Na consulta ao catálogo do Datasus, foram localizados 262 sistemas informatizados; após análise da descrição sumária e principais objetivos, foram selecionados 12 sistemas que geram dados sobre dispositivos médicos. A falta de interoperabilidade dos sistemas é recorrente e a ausência de uma nomenclatura padronizada é um desafio a mais. Conclusão: Há crescente discussão do uso de RWD para subsidiar ATS em todo o ciclo de vida tecnológico, desde regulação até monitoramento do uso, como também para subsidiar análises de custo-efetividade e benefícios clínicos. Assim como nos demais países, o Brasil sistematizou inicialmente os dados administrativos para atender às demandas comerciais e financeiras. Os sistemas não geram dados dos resultados clínicos. São disponibilizados dados das tecnologias dispensadas e dos valores repassados e não são coletadas as informações dos benefícios do uso dessas tecnologias. Com a evolução dos métodos de ATS, a utilização de RWD tornou-se relevante.

Objective: It was intended to map government databases on medical devices, in the public perspective, in order to contribute as a source to generate real world data (RWD) and potential to subsidize Health Technology Assessment (HTA) studies. Methods: A narrative review was carried out in the Embase database. The criteria for inclusion of eligibility were: i) broad dimension of RDW in technology management processes; and ii) application of RDW in regulatory processes, coverage and HTA. The systems of the Ministry of Health and Anvisa were also consulted. Results: Results: The search returned 1,185 results, after reading the abstracts, 29 articles were selected, 5 of which were included. The catalog of Datasus database were consulted, 262 summaries with the description and the main objectives were analyzed, 12 systems were selected systems that generate medical devices. The lack of interoperability of systems is recurrent and the absence of a standardized nomenclature is an additional challenge. Conclusion: There is a growing discussion about the use of RWD to subsidize HTA throughout the technological life cycle, from regulation to monitoring of use, as well as to subsidize the examination of cost-effectiveness and clinical benefits. As in other countries, Brazil has systematized administrative data for commercial and financial data demands. The systems do not generate data on clinical outcomes. Data provided are on dispensed technologies, on transferred values and are not collected on the benefits of using these technologies. With the evolution of HTA methods, the use of RWD has become relevant.

Mapeamento dos bancos de dados em dispositivos médicos: revisão narrativa e o cenário brasileiro para avaliação com dados de mundo real (RWD) / Mapping of database in medical devices: review and the Brazilian scenario for evaluation with real world data (RWD)

Objetivo: Pretendeu-se mapear os bancos de dados governamentais em dispositivos médicos, na perspectiva pública com o intuito de contribuir como fonte para gerar dados de mundo real (RWD) e potencial para subsidiar estudos de Avaliação de Tecnologias em Saúde (ATS). Métodos: Realizada revisão narrativa na base de dados do Embase. Os critérios para inclusão de elegibilidade foram: i) dimensão ampla de RDW nos processos de gestão de tecnologias; e ii) aplicação de RDW em processos regulatórios, cobertura e ATS. Também foram consultados os sistemas do Ministério da Saúde e da Anvisa. Resultados: A busca retornou 1.185 resultados; após leitura dos resumos, foram selecionados 29 artigos, sendo 5 incluídos. Na consulta ao catálogo do Datasus, foram localizados 262 sistemas informatizados; após análise da descrição sumária e principais objetivos, foram selecionados 12 sistemas que geram dados sobre dispositivos médicos. A falta de interoperabilidade dos sistemas é recorrente e a ausência de uma nomenclatura padronizada é um desafio a mais. Conclusão: Há crescente discussão do uso de RWD para subsidiar ATS em todo o ciclo de vida tecnológico, desde regulação até monitoramento do uso, como também para subsidiar análises de custo-efetividade e benefícios clínicos. Assim como nos demais países, o Brasil sistematizou inicialmente os dados administrativos para atender às demandas comerciais e financeiras. Os sistemas não geram dados dos resultados clínicos. São disponibilizados dados das tecnologias dispensadas e dos valores repassados e não são coletadas as informações dos benefícios do uso dessas tecnologias. Com a evolução dos métodos de ATS, a utilização de RWD tornou-se relevante.

The Role of Societal Aspects in the Formation of Official COVID-19 Reports: A Data-Driven Analysis.

This paper investigates the role of socioeconomic considerations in the formation of official COVID-19 reports. To this end, we employ a dataset that contains 1159 pre-processed indicators from the World Bank Group GovData360 and TCdata360 platforms and an additional 8 COVID-19 variables generated based on reports from 138 countries. During the analysis, a rank-correlation-based complex method is used to identify the time- and space-varying relations between pandemic variables and the main topics of World Bank Group platforms. The results not only draw attention to the importance of factors such as air traffic, tourism, and corruption in report formation but also support further discipline-specific research by mapping and monitoring a wide range of such relationships. To this end, a source code written in R language is attached that allows for the customization of the analysis and provides up-to-date results.

Explaining health system responses to public reporting of cardiac surgery mortality in England and the USA.

Public reporting of clinical performance is increasingly used in many countries to improve quality and enhance accountability of the health system. The assumption is that greater transparency will stimulate improvements by clinicians in response to peer pressure, patient choice or competition. The international diffusion of public reporting might suggest greater similarity between health systems. Alternatively, national and local contexts (including health system imperatives, professional power and organisational culture) might continue to shape its form and impact, implying continued divergence. The paper considers public reporting in the USA and England through the lens of Scott's 'pillars' institutional framework. The USA was arguably the first country to adopt public reporting systematically in the late 1980s. England is a more recent adopter; it is now being widely adopted through the National Health Service (NHS). Drawing on qualitative data from California and England, this paper compares the behavioural and policy responses to public reporting by health system stakeholders at micro, meso and macro levels and through the intersection of ideas, interests, institutions and individuals through. The interplay between the regulative, normative and cultural-cognitive pillars helps explain the observed patterns of on-going divergence.

Quality versus Risk-of-Bias assessment in clinical research.

Assessment of internal validity safeguards implemented by researchers has been used to examine the potential reliability of evidence generated within a study. These safeguards protect against systematic error, and such an assessment has traditionally been called a quality assessment. When the results of a quality assessment are translated through some empirical construct to the potential risk of bias, this has been termed a risk of bias assessment. The latter has gained popularity and is commonly used interchangeably with the term quality assessment. This key concept paper clarifies the differences between these assessments and how they may be used and interpreted when assessing clinical evidence for internal validity.

Funding and public reporting strategies for reducing multiple pregnancy from fertility treatments.

The health of children born through assisted reproductive technologies (ART) is particularly vulnerable to policy decisions and market forces that play out before they are even conceived. ART treatment is costly, and public and third-party funding varies significantly between and within countries, leading to considerable variation in consumer affordability globally. These relative cost differences affect not only who can afford to access ART treatment, but also how ART is practiced in terms of embryo transfer practices, with less affordable treatment creating a financial incentive to transfer more than one embryo to maximize the pregnancy rates in fewer cycles. One mechanism for reducing the burden of excessive multiple pregnancies is to link insurance coverage to the number of embryos that can be transferred; another is to combine supportive funding with patient and clinician education and public reporting that emphasizes a "complete" ART cycle (all embryo transfers associated with an egg retrieval) and penalizes multiple embryo transfers. Improving funding for fertility services in a way that respects clinician and patient autonomy and allows patients to undertake a sufficient number of cycles to minimize moral hazard improves outcomes for mothers and babies while reducing the long-term economic burden associated with fertility treatments.

Quality Measure Public Reporting Is Associated with Improved Outcomes Following Hip and Knee Replacement.

BACKGROUND: Given the inclusion of orthopaedic quality measures in the Centers for Medicare & Medicaid Services national hospital payment programs, the present study sought to assess whether the public reporting of total hip arthroplasty (THA) and total knee arthroplasty (TKA) risk-standardized readmission rates (RSRRs) and complication rates (RSCRs) was temporally associated with a decrease in the rates of these outcomes among Medicare beneficiaries. METHODS: Annual trends in national observed and hospital-level RSRRs and RSCRs were evaluated for patients who underwent hospital-based inpatient hip and/or knee replacement procedures from fiscal year 2010 to fiscal year 2016. Hospital-level rates were calculated with use of the same measures and methodology that were utilized in public reporting. Annual trends in the distribution of hospital-level outcomes were then examined with use of density plots. RESULTS: Complication and readmission rates and variation declined steadily from fiscal year 2010 to fiscal year 2016. Reductions of 33% and 25% were noted in hospital-level RSCRs and RSRRs, respectively. The interquartile range decreased by 18% (relative reduction) for RSCRs and by 34% (relative reduction) for RSRRs. The frequency of risk variables in the complication and readmission models did not systematically change over time, suggesting no evidence of widespread bias or up-coding. CONCLUSIONS: This study showed that hospital-level complication and readmission rates following THA and TKA and the variation in hospital-level performance declined during a period coinciding with the start of public reporting and financial incentives associated with measurement. The consistently decreasing trend in rates of and variation in outcomes suggests steady improvements and greater consistency among hospitals in clinical outcomes for THA and TKA patients in the 2016 fiscal year compared with the 2010 fiscal year. The interactions between public reporting, payment, and hospital coding practices are complex and require further study. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks.

Several systematic reviews (SRs) have been conducted on the COVID-19 outbreak, which together with the SRs on previous coronavirus outbreaks, form important sources of evidence for clinical decision and policy making. Here, we investigated the methodological quality of SRs on COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). Online searches were performed to obtain SRs on COVID-19, SARS, and MERS. The methodological quality of the included SRs was assessed using the AMSTAR-2 tool. Descriptive statistics were used to present the data. In total, of 49 SRs that were finally included in our study, 17, 16, and 16 SRs were specifically on COVID-19, MERS, and SARS, respectively. The growth rate of SRs on COVID-19 was the highest (4.54/month) presently. Of the included SRs, 6, 12, and 31 SRs were of moderate, low, and critically low quality, respectively. SRs on SARS showed the optimum quality among the SRs on the three diseases. Subgroup analyses showed that the SR topic (P < .001), the involvement of a methodologist (P < .001), and funding support (P = .046) were significantly associated with the methodological quality of the SR. According to the adherence scores, adherence to AMSTAR-2 items sequentially decreased in SRs on SARS, MERS, and COVID-19. The methodological quality of most SRs on coronavirus outbreaks is unsatisfactory, and those on COVID-19 have higher risks of poor quality, despite the rapid actions taken to conduct SRs. The quality of SRs should be improved in the future. Readers must exercise caution in accepting and using the results of these SRs.

Assessment of repeat target lesion percutaneous coronary intervention as a quality measure for public reporting and general quality assessment for PCIs.

BACKGROUND: Target lesion percutaneous coronary intervention (TLPCI) within 1 year of PCI has been proposed by critics of public reporting of short-term mortality as an alternative measure for PCI reporting. METHODS: New York's PCI registry was used to identify 1-year repeat TLPCI and 1-year repeat TLPCI/mortality for patients discharged between December 1, 2013 and November 30, 2014. Significant independent predictors of the outcomes were identified. Hospital and cardiologist risk-adjusted outcomes were calculated, and outlier status and correlations of risk-adjusted rates were examined for the three outcomes. RESULTS: The adverse outcome rates were 1.30, 4.21, and 8.97% for in-hospital/30-day mortality, 1-year repeat TLPCI, and 1-year repeat TLPCI/mortality. There were many commonalities but also many differences in significant predictors of the outcomes. Hospital and cardiologist risk-adjusted 1-year repeat TLPCI rates and repeat TLPCI/mortality rates were poorly correlated with risk-adjusted in-hospital/30-day mortality rates (eg, Spearman R = -.16 [p = .23] and .27 [p = .04], respectively, for hospital 1-year repeat TLPCI vs. in-hospital/30-day mortality). Many more providers were found to have significantly higher and lower rates for repeat TLPCI than for short-term mortality. CONCLUSIONS: Hospital and cardiologist quality assessments are very different for TLPCI and repeat TLPCI/mortality than they are for short-term mortality. Repeat TLPCI/mortality rates are highly correlated with repeat TLPCI rates, but outlier providers differ. More study of repeat TLPCI and all the patient, cardiologist, and hospital factors associated with it may be required before using it as a supplement to, or in lieu of, short-term mortality in public reporting of PCI outcomes.

Hospital Response to CMS Public Reports of Hospital Charge Information.

BACKGROUND: In an effort to increase price transparency, the Centers for Medicare and Medicaid Services (CMS) began reporting charges for Medicare inpatients treated in ∼3400 hospitals online in 2013. As of 2019, CMS began to require hospitals themselves to publicize a more comprehensive list of their underlying procedure charges. OBJECTIVE: The objective of this study was to assess the responses of hospitals to broad-scale public reporting of their charges for inpatient services. RESEARCH DESIGN: We used descriptive analysis to examine the trend in CMS charge data for high charge hospitals before and after the 2013 intervention. We also applied difference-in-differences analysis to comprehensive inpatient charge data from New York and Florida for the years 2011-2016, defining the reported high-volume diagnosis-related groups (DRGs) as the intervention group. RESULTS: At the national level, the CMS charge data showed relatively lower growth in high charge hospitals following the intervention. From the state data, we found that after 3 years, the growth in charges for reported DRGs in New York hospitals was 4%-9% lower than for unreported diagnosis-related groups. In Florida, it was 2%-8% lower. CONCLUSION: Public reports of hospital inpatient charges by DRG appear to influence subsequent charges, slowing their growth.

RDQA 2º Quadrimestre de 2020 Relatório Detalhado do Quadrimestre Anterior da Secretaria de Saúde do Estado do Tocantins / RDQA 2nd Quadrimester of 2020 Detailed Report of the Previous Quadrimester of the State Health Department of Tocantins

O Relatório Detalhado do Quadrimestre Anterior (RDQA) apresentam os resultados alcançados com a execução da PAS a cada quadrimestre e orientam eventuais redirecionamentos. Eles têm a função de comprovar a aplicação de todos os recursos do Fundo de Saúde. É instrumento indissociável do Plano e de suas respectivas Programações, sendo a principal ferramenta para subsidiar o processo de monitoramento e avaliação da gestão. Tem seu modelo padronizado pela Resolução nº 459 do Conselho Nacional de Saúde - CNS, de 10 de outubro de 2012, publicada no DOU de 21/12/2012, conforme dispõe o Parágrafo 4º do Artigo 36 da Lei Complementar nº 141/2012. A Programação Anual de Saúde (PAS) é a referência de execução das ações e serviços públicos em saúde, cujo processo de sua gestão é demonstrado no Relatório de Gestão: a cada quadrimestre no RDQA e ao final do exercício no Relatório Anual de Gestão (RAG).

The Detailed Report for the Previous Quadrimester (RDQA) presents the results achieved with the execution of the PAS every four months and guides any redirections. They have the function of proving the application of all the resources of the Health Fund. It is an inseparable instrument of the Plan and its respective Programs, being the main tool to support the process of monitoring and evaluation of management. Its model is standardized by Resolution No. 459 of the National Health Council - CNS, of October 10, 2012, published in the DOU of 12/21/2012, as provided in Paragraph 4 of Article 36 of Complementary Law No. 141/2012. The Annual Health Program (PAS) is the benchmark for executing public health actions and services, whose management process is demonstrated in the Management Report: every four months in the RDQA and at the end of the year in the Annual Management Report (RAG) ).

El Informe Detallado del Cuatrimestre Anterior (RDQA) presenta los resultados obtenidos con la ejecución del PAS cada cuatro meses y orienta las redirecciones. Tienen la función de acreditar la aplicación de todos los recursos del Fondo de Salud, instrumento inseparable del Plan y sus respectivos Programas, siendo la principal herramienta de apoyo al proceso de seguimiento y evaluación de la gestión. Su modelo se encuentra estandarizado por la Resolución No. 459 del Consejo Nacional de Salud - CNS, de 10 de octubre de 2012, publicada en el DOU de 21/12/2012, según lo dispuesto en el numeral 4 del artículo 36 de la Ley Complementaria No. 141/2012. El Programa Anual de Salud (PAS) es el referente para la ejecución de acciones y servicios de salud pública, cuyo proceso de gestión se demuestra en el Informe de Gestión: cuatrimestral en el RDQA y al final del año en el Informe Anual de Gestión (RAG) ).

Le rapport détaillé du quadrimestre précédent (RDQA) présente les résultats obtenus avec l'exécution du PAS tous les quatre mois et guide les éventuelles réorientations. Ils ont pour fonction de prouver l'application de toutes les ressources du Fonds de la Santé, instrument indissociable du Plan et de ses Programmes respectifs, étant le principal outil d'appui au processus de suivi et d'évaluation de la gestion. Son modèle est normalisé par la résolution n ° 459 du Conseil national de la santé - CNS du 10 octobre 2012, publiée au DOU du 21/12/2012, comme prévu au paragraphe 4 de l'article 36 de la loi complémentaire n ° 141/2012. Le Programme Annuel de Santé (PAS) est la référence pour la mise en œuvre d'actions et de services de santé publique, dont le processus de gestion est démontré dans le rapport de gestion: tous les quatre mois dans le RDQA et en fin d'année dans le rapport annuel de gestion (RAG) ).

Americans' Growing Exposure To Clinician Quality Information: Insights And Implications.

For two decades, various initiatives have encouraged Americans to consider quality when choosing clinicians, both to enhance informed choice and to reduce disparities in access to high-quality providers. The literature portrays these efforts as largely ineffective. But this depiction overlooks two factors: the dramatic expansion since 2010 in the availability of patients' narratives about care and the growth of information seeking among consumers. Using surveys fielded in 2010, 2014, and 2015, we assessed the impact of these changes on consumers' awareness of quality information and sociodemographic differences. Public exposure to any quality information doubled between 2010 and 2015, while exposure to patient narratives and experience surveys tripled. Reflecting a greater propensity to seek quality metrics, minority consumers remained better informed than whites over time, albeit with differences across subgroups in the types of information encountered. An education-related gradient in quality awareness also emerged over the past decade. Public policy should respond to emerging trends in information exposure, establish standards for rigorous elicitation of narratives, and assist consumers' learning from a combination of narratives and quantified metrics on clinician quality.

Impact of Oncology Drug Shortages on Chemotherapy Treatment.

Prescription drug shortages began to increase markedly in the mid-2000s, including sterile injectable products such as chemotherapy drugs. Using Medicare claims linked to Surveillance Epidemiology and End Results (SEER), we examined outpatient chemotherapy use during shortage periods relative to the months before and after a shortage for newly diagnosed patients with breast, colorectal, leukemia, lung, lymphoma, ovarian, or pancreatic cancer (N = 182,470). For most drugs, we found little impact of shortages on either the fraction of patients receiving that drug or the quantity provided. In some cases, we found declines in utilization: 4% for doxorubicin and fluorouracil; 2.9% for oxaliplatin; and about 1% for cytarabine, dacarbazine, and leuprolide. Although shortages for a few drugs resulted in substantial reductions in use, in most cases, they resulted in little to no reduction. We discuss potential explanations for these counterintuitive findings, including potential limitations of current drug shortage reporting methods.

Health systems and public health services

Strengthening health systems and public health servicesis at the core of WHO´s work with countries and with theregional and global health community. In the WHO EuropeanRegion, Member States committed to strengthening healthsystems for better health and wealth by signing the TallinnCharter in June 2008.The WHO Regional Office for Europe supports MemberStates in developing such synergies through a variety ofmeans including support to national policy frameworks,and the various key aspects of health systems such asgovernance, public health services, health financing, humanresource, primary health care, information systems, researchand quality assurance.